Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 5, 2005, Pages 497-501

  Veronese, Maria Luisa ^a   Flaherty, Keith ^a   Kramer, Amy ^a   Konkle, Barbara A ^a   Morgan, Mark ^a   Stevenson, James P ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CT 2103; Neurotoxicity; Phase I; Taxanes

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; POLYGLUTAMATE PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LONG TERM CARE; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYGLUTAMIC ACID; TAXOIDS; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 17644364728     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0938-3     Document Type: Article

References (22)

1. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004-1014
2. Rowinsky EK, Einsenhauer EA, Chaudhry V, et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15
3. Weiss RB, Donehower RC, Wiernik PH, et al (1990) Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268
4. Sparreboom A, van Zuylen L, Brouwer E, et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454-1457
5. Gelderblom H, Verweij J, Nooter K, et al (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598
6. Dye D, Watkins J (1980) Suspected anaphylactic reaction to Cremophor EL. BMJ 280:1353
7. Lorenz W, Reimann H-J, Schmal A, et al (1977) Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7:63-67
8. Howrie DL, Ptachcinski RJ, Griffith BP, et al (1985) Anaphylactoid reactions associated with parenteral cyclosporine use. Possible role of Cremophor EL. Drug Intell Clin Pharm 19:425-427
9. Duncan R (1992) Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3:175-210
10. Cassidy J, Newell DR, Wedge SR, Cummings J (1993) Pharmacokinetics of high molecular weight agents. Cancer Surv 17:315-341
11. Matsumura Y, Maeda H (1986) A new concept for macro-molecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387-6392
12. McCormick-Thomson LA, Duncan R (1989) Poly (amino acid) copolymers as a potential soluble drug delivery system. 1. Pinocytic uptake and lysosomal degradation measured in vitro. J Bioact Compat Polym 4:242-251
13. Li C, Yu DF, Newman RA, et al (1998) Complete regression of well established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res 58:2404-2409
14. Li C, Price JE, Milas L, et al (1999) Antitumor activity of poly (L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 5:891-897
15. Verrill MW, Boddy AV, Todd R, et al (2003) Phase I pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors (abstract 533). Proc Am Soc Clin Oncol 22:133
16. Bolton MG, Nemunaitis J (2003) Phase I study of CT-2103/carboplatin in patients with solid tumors. Proc Am Soc Clin Oncol 22:133(A646)
17. Kudelka A, Skubitz KM, Kavanegh JJ, et al (2003) Phase I study of CT-2103/cisplatin in patients with solid tumors (abstract 1841). Proc Am Soc Clin Oncol 22:133
18. Shipley D, Greco A, Jones S, et al (2003) Phase I study of CT-2103 in patients with non-small cell lung cancer (abstract 2833). Proc Am Soc Clin Oncol 22:133
19. Robson L, Verrill M, Lind MJ, et al (2003) A phase II study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer (abstract 169). Proc Am Soc Clin Oncol 22:133
20. Schulz JJ, Burris HA, Redfern C, et al (2003) Phase II study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen (abstract 1137). Proc Am Soc Clin Oncol 22:133
21. Norton MS, Neubauer M, Harper H, et al (2003) Phase 2 study of first line chemotherapy using CT-2103 in patients with non-small cell lung cancer who are ≥70 years of age or performance status (PS) = 2 (abstract 2626). Proc Am Soc Clin Oncol 22:133
22. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216